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Abstract
Background: We aimed to prospectively assess the influence of the recommended dose, 1.0 g 
of polyunsaturated fatty acids (N-3 PUFA) daily, on platelet reactivity in patients with stable 
angina pectoris (SAP) after elective percutaneous coronary intervention (PCI).
Methods: Forty consecutive patients with SAP and successful PCI were randomized to the study 
group (group PUFA: n = 20; age 65 ± 8; standard therapy + 75 mg acetylsalicylic acid + 75 mg  
clopidogrel + N-3 PUFA/Omacor 1 g daily) and the control group (group C: n = 20; age  
65 ± 9; standard therapy + 75 mg acetylsalicylic acid + 75 mg clopidogrel). Platelet reactivity 
tests (COL, TRAP, ASPI, ADP) were performed using whole blood aggregometry (multiplate 
platelet [PLT] function analysis) on the 2nd and 30th day after PCI. 
Results: Baseline patients’ characteristics and clinical outcomes were comparable between 
the groups. There were no differences between both groups in the mean values of the PTL tests 
measured 30 days after PCI (PUFA vs. C: ASPI: 18.5 ± 17 vs. 27 ± 29 U, COL: 30.4 ± 14.3 
vs. 30.3 ± 13.4 U, ADP: 25.4 ± 16.1 vs. 20 ± 10.7 U, TRAP: 65.8 ± 25.6 vs. 57.1 ± 20.4 U, 
p = NS). The mean delta values of the PTL tests (18–24 h post-PCI/30 days post-PCI) were 
also comparable between the groups. The PTL aggregometry results were related to time — the 
baseline values of the ADP (p = 0.003), COL (p = 0.037) and TRAP (p < 0.001) tests were 
smaller and the ASPI (p = 0.027) test was higher than those measured after 1-month. 
Conclusions: N-3 PUFA supplementation does not affect the efficacy of dual antiplatelet 
therapy in patients with SAP after PCI. (Cardiol J 2013; 20, 5: 478–485)
Key words: N-3 polyunsaturated fatty acids, antiplatelet therapy, aggregometry, 
percutaneous coronary intervention
Introduction
Dual antiplatelet therapy with acetylsalicylic 
acid (ASA) and clopidogrel (CLO) is recommended 
after percutaneous coronary intervention (PCI) 
with stent implantation to reduce the risk of in-
stent thrombosis [1, 2]. Despite dual antiplatelet 
therapy, some patients experience thrombotic 
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cardiac events. Thus, agents that reduces the risk 
of thrombotic events without increasing the risk 
of bleeding merits further evaluation. 
N-3 polyunsaturated fatty acids (N-3 PUFA) 
supplementation is well-established and widely 
used in the primary and secondary prevention of 
cardiovascular diseases [2, 3]. It was demonstrated 
that N-3 PUFA may affect the coagulation, but in 
higher doses compared to the standard supple-
mentation dose [4, 5]. Most studies evidenced 
their antithrombotic effects [6–9] with no excess 
in clinically significant bleeding risk [10–12]. The 
available studies provide inconsistent results on 
antiplatelet N-3 PUFA action [13–15]. According to 
the recently published data, a short — 1-month N-3 
PUFA therapy — significantly improved platelet 
response to clopidogrel after PCI [16, 17]. As fish 
oil consumption and N-3 PUFA supplementation 
are recommended for the secondary prevention of 
cardiovascular events [2], the potential antiplatelet 
effects would be of great importance for patients 
on dual antiplatelet therapy. 
There are several platelet (PTL) function tests 
available. Whole blood impedance aggregometry 
(WBA) is one of the new methods with a high sensi-
tivity for antiplatelet drugs (ASA, CLO, Prasugrel, 
IIb/IIIa antagonist). WBA may be a reliable tool in 
the assessment of N-3 PUFA and ASA/CLO interac-
tions, but the evidence is scarce [18]. WBA is based 
on PTL activation stimulated in vitro with different 
agonists: arachidonic acid (AA) in the ASPI test, 
collagen in the COL test, ADP in the ADP test and 
a thrombin receptor activating peptide (TRAP-6) in 
the TRAP test. PLT response to CLO is well evalu-
ated by the ADP and indirectly by the TRAP tests. 
The assessment of ASA antiplatelet effectiveness 
is measured using the ASPI and COL tests.
Reassuming, there are also some data on N-3 
PUFA induced PTL inhibition in the literature. 
The daily doses of N-3 PUFA administered in most 
studies were high and therefore the influence of the 
standard recommended dose of 1.0 g daily is of great 
interest, especially because WBA as a laboratory 
PTL function assay is now available and may serve 
as a useful tool in the evaluation of PTL-N-3 PUFA 
interactions. Thus, the objective of the study was to 
assess the influence of N-3 PUFA therapy on PLT 
reactivity to ASA and CLO measured using WBA in 
patients with stable angina pectoris (SAP) after PCI.
Methods
The study population consisted of 40 consecu-
tive patients with SAP (Canadian Cardiovascular 
Society [CCS] I–III) and successful PCI with stent 
(bare metal stent [BMS] or drug eluting stent 
[DES]) implantation. The standard pharmaco-
therapy used before the study enrollment was 
similar for both groups, including ASA (75 mg 
daily) for at least 3 months prior to the study and 
CLO with loading dose (600 mg) in the day of PCI 
procedure followed by daily doses of 75 mg during 
the study. The patients were randomized into two 
study groups: group PUFA (female/male = 8/12; 
age 65 ± 8) with N-3 PUFA (Omacor 1 g daily) 
supplementation started 24 h after CLO loading 
dose and the control group matched as to age and 
sex (female/male = 6/15; age 65 ± 90) (Fig. 1). 
Standard pharmacotherapy following the European 
Society of Cardiology (ESC) recommendations was 
given to all of the patients: ASA (75 mg/d), CLO 
(75 m/d), statin, beta-blocker and angiotensin con-
verting enzyme-inhibitors (ACE-I) were adjusted 
to heart rate and blood pressure.
The exclusion criteria included: acute coronary 
syndrome (ACS), cardiac troponin I concentration 
> 0.01 ng/mL, a history of myocardial infarction 
(MI) within 6 months prior to the enrollment into 
the study, acute and chronic inflammatory diseases 
(in the 3 preceding months), 2nd and 3rd degree of 
hypertension according to the ESC guidelines, 
myocarditis and vasculitis, current gastrointestinal 
tract diseases, diseases of the aorta, hormone re-
placement therapy, spondyloarthritis, hematologi-
cal disorders, underlying malignancies, comorbid 
psychiatric or neurological disorders, treatment 
with GP IIb/IIIa inhibitors, oral anticoagulant 
therapy, acute and chronic kidney disease (glo-
merular filtration rate < 60 mL/min/1.73 m2), use 
of nonsteroid anti-inflammatory drugs and steroids. 
All the patients gave the written informed 
consent, and our study protocol was approved 
by our institution’s human research committee, 
conformed to the ethical guidelines by the 1975 
Declaration of Helsinki.
All of the subjects had a clinical assessment 
comprising a detailed medical history (family his-
tory, previous ST/non-ST elevation myocardial 
infarction [STEMI/NSTEMI], previous coronary 
artery by-pass grafting [CABG], concomitant 
diseases, smoking status, pharmacotherapy) and 
a physical examination. Anthropometric measure-
ments were obtained and body mass index (BMI) 
and waist to hip ratio (WHR) were calculated. The 
standard diagnostic tests (ECG, TTE) were done. 
Echocardiography was performed in all patients 
according to the guidelines of the European Society 
of Echocardiography. PCI was performed using the 
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standard protocols. Clinical data (CCS class, inci-
dence of unstable angina, MI, re-PCI, CABG, death) 
as well as compliance with the study drug admin-
istration was verified at the 1-month follow-up.
Blood samples were obtained in the morning 
after fasting from the cubital vein in supine pa-
tients into 5–10 mL blood collection tubes using 
venipuncture. Blood morphology was assessed 
manually in a local laboratory at hospital admission. 
Platelet function analysis was performed us-
ing the Multiplate analyzer — Multiple Electrode 
Aggregometry (MEA) and a point-of-care whole 
blood impedance aggregometer (Dynabate, Munich, 
Germany). The baseline PTL function analysis was 
assessed 18–24 h after the PCI + CLO loading dose 
(600 mg) and before administration of N-3 PUFA. The 
second sample was obtained 30 days after PCI (stan- 
dard therapy as was mentioned earlier). In the imped-
ance aggregometry method, resting blood platelets 
are activated by particular agonists, expose receptors 
and attach to the test surfaces. The analyzer con-
tinuously measures the resistance which correlates 
with the platelets adhering to the electrodes. The 
procedure includes 300 mL whole blood and 300 mL 
saline 0.9%, preheated at 37°C and incubated for 
180 s, afterwards 20 mL of the particular agonist solution 
is added and the test is performed (6 min). The final 
concentration of the test solutions were as follows: 
ADP 6.5 mM (ADP test), COL 3.2 mg/mL (COL test), 
AA 0.5 mM (ASPI test), TRAP 32 mM (TRAP test). 
The analyzer has 5 cells for parallel testing.
WBA was performed with the same kit to avoid 
inter-kit variability.
Statistical analysis
All text and table results are expressed as 
means ± standard deviation (SD) for normally dis-
tributed variables and as medians for abnormally 
distributed variables or as a number and percentage. 
The results’ normal distribution was analyzed using 
the Kolmogorov-Smironov test. Baseline clinical 
parameters and the results of ancillary investiga-
tions were compared using the to-sample t-tests for 
normally distributed continuous variables (Student’s 
t-test); in the case of abnormal distribution, the 
Mann-Whitney U test was used. To compare the 
change of PTL function tests over time, the data 
were analyzed as repeated measures analysis of 
variances, taking into account intervention factors 
and time. The Spearman rank model was used for 
correlation analysis of the baseline (PTL tests re-
sults — data obtained at 1 day after PCI) parameters. 
The Pearson model was used to determine the rela-
tionships between the delta values of the variables 
(18–24 h post-PCI/30 days post-PCI). Multivariable 
linear regression was used to assess independent 
predictors of the PTL function tests as well as the 




There were no significant differences between 
both groups in baseline demographics (PUFA: 
n = 20; age: 65 ± 8.5; F/M: 8/12; BMI: 29.6 kg/m2; 
WHR 0.98 vs. C: n = 20; age: 64 ± 8.4, F/M: 6/14; 
BMI: 29.3 kg/m2; WHR: 0.95; p = NS), medical 
Figure 1. Participant flow; ASA — acetylsalicylic acid; CLO — clopidogrel; PCI — percutaneous coronary 
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(PUFA: mean CCS: 2.1 ± 0.4; previous STEMI/ 
/NSTEMI: 7/1; previous CABG: 0 vs. C: mean CCS: 
2.2 ± 0.6; STEMI/NSTEMI: 8/0; previous CABG: 
2; p = NS) characteristics, concomitant diseases, 
laboratory tests (Tables 1, 2), pharmacotherapy 
(Table 3), echocardiographic findings (left ven-
tricular ejection fraction: PUFA: 59 ± 7% vs. C: 
56 ± 9%). Successful PCI with stent implantation 
(thrombolysis in myocardial infarction — TIMI 3 
flow) was performed in all patients (PUFA: BMS: 
18, DES: 2 vs. C: BMS: 19 vs. DES: 1; p = NS). 
The baseline values of PTL function tests as-
sessed 18–24 h after the CLO loading dose were 
comparable between the groups (Table 4). 
Main outcomes after 1-month therapy
The clinical outcome was comparable between 
the study groups; there were no differences in CCS 
class. No incidence of unstable angina, MI, re-PCI, 
urgent CABG or death were noted. 
In the ANOVA analysis, we found no associa-
tions between the PTL test results and the group 
Table 1. Group PUFA and group C baseline characteristics.
  Group PUFA (n = 20) Group C (n = 20) P
Age [years] 65 ± 8.5 64.4 ± 8.4 NS
Female/male 8 (40%)/12 (60%) 6 (30%)/14 (70%) NS
Body mass index [kg/m2] 29.6 ± 3.8 29.3 ± 4.2 NS
Waist-to-hip ratio 0.98 ± 0.09 0.95 ± 0.11 NS
Hypertension 18 (90%) 17 (85%) NS
Hyperlipidemia 18 (90%) 16 (90%) NS
Diabetes mellitus 7 (35%) 6 (30%) NS
Current smoking 5 (25%) 7 (35%) NS
STEMI/NSTEMI in medical history 7 (35%)/1 (5%) 8 (40%)/0 (0%) NS
CABG in medical history 0 (0%) 2 (10%) NS
Total cholesterol [mg/dL] 164.8 ± 48.1 171 ± 71 NS
Low density lipoprotein [mg/dL] 91.4 ± 41.2 93.2 ± 51 NS
High density lipoprotein [mg/dL] 39.4 ± 19.3 35.5 ± 12.3 NS
Triglicerydes [mg/dL] 147.3 ± 64.3 162 ± 71.4 NS
Red blood cells [× 106/µL] 4.5 ± 0.5 4.7 ± 0.3 NS
White blood cells [× 103/µL] 7.3 ± 2.5 6.8 ± 1.2 NS
Creatinine [mg/dL] 0.9 ± 0.3 0.9 ± 0.2 NS
End-diastolic diameter [mm] 50.6 ± 4.5 48.3 ± 6.3 NS
End-systolic diameter [mm] 30.7 ± 6.5 32.4 ± 5.9 NS
Ejection fraction [%] 59.4 ± 6.9 55.5 ± 8.7 NS
STEMI — ST elevation myocardial infarction; NSTEMI — non ST elevation myocardial infarction; CABG — coronary artery bypass graft
Table 2. Group PUFA and group C baseline platelets laboratory tests.
Standard laboratory tests Group PUFA (n = 20) Group C (n = 20) P
Mean ± SD 25/75  
percentile
Mean ± SD 25/75  
percentile
Platelets (× 103/µL) 168.4 ± 59.9 118.5/223 190.9 ± 23.6 174/202 NS
Platelet distribution width [fl] 13.1 ± 2.5 11.9/13.6 12.3 ± 1.5 11.3/13.5 NS
Mean platelet volume [fl] 10.7 ± 0.9 10/11.8 10.4 ± 0.7 10/10.9 NS
Large platelets [%] 30 ± 6.8 25.5/32.3 27.6 ± 5.3 25.5/32.7 NS
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(PUFA or C). The PTL aggregometry results were 
related to the time of observation — the baseline 
values of the ADP (p = 0.003), COL (p = 0.037) 
and TRAP (p < 0.001) tests were smaller and the 
ASPI (p = 0.027) test was higher than those mea-
sured after the 1-month observation (Table 4). The 
mean delta values of PTL tests results were also 
comparable between the groups (Table 5). 
Regression analysis
Clinical data. The TRAP test values were 
correlated with patients’ age (r = 0.354, p = 0.021). 
The COL test results were correlated with HDL-
-cholesterol levels (r = –0.263, p = 0.033) and in 
a borderline manner to creatinine serum levels 
(r = 0.229, p = 0.064). Significant correlations be-
tween the delta PTL test results and serum creati-
nine levels were also found. The serum creatinine 
level correlated with delta ASPI and delta COL 
(r = 0.440, p = 0.05 and r = 0.456, p = 0.046) in 
the PUFA group and with delta ADP and delta ASPI 
(r = –0.650, p = 0.007 and r = –0.533, p = 0.028) 
in the group C.
PTL count, volume and morphology. Sig-
nificant correlations between the delta PTL test 
results and PTL count, volume and morphology 
Table 3. Group PUFA and group C pharmacotherapy.
Group PUFA (n = 20) Group C (n = 20) P
Acetylsalicylic acid 20 (100%) 20 (100%) NS
Clopidogrel 20 (100%) 20 (100%) NS
Beta-blocker 19 (95) 18 (90%) NS
Angiotensin converting enzyme inhibitor 20 (100%) 20 (100%) NS
Diuretics 8 (40%) 12 (60%) NS
Statin 20 (100%) 20 (100%) NS
Fibrate 4 (20%) 8 (40%) NS
Oral diabetes mellitus drugs 7 (35%) 6 (30%) NS
Nitroglycerin 4 (20%) 4 (20%) NS
Table 4. ANOVA analysis — interaction of time and intervention in the study groups.
Test* Group PUFA (n = 20) Group C (n = 20) P Source of variatione
Baseline After  
1 month








ADP [U] 25.5 ± 16.0 29.3 ± 13.2 20.0 ± 10.7 25.0 ± 8.3 017 0.003 0.34
ASPI [U] 18.5 ± 17.0 26.9 ± 20.7 27.0 ± 28.8 23.1 ± 13.9 0.94 0.027 0.69
COL [U] 30.5 ± 14.3 33.2 ± 8.6 30.3 ± 13.4 33.1 ± 7.9 0.97 0.037 0.92
TRAP [U] 65.8 ± 25.6 80.1 ± 20.7 67.1 ± 20.4 85.3 ± 23.6 0.69 < 0.001 0.66
*Platelets activity tests with different activators: arachidonic acid (ASPI), adenosine diphosphate (ADP), thrombin receptor activating  
  peptide-6 (TRAP), collagen (COL). 
Table 5. Comparison of delta platelet test results (baseline and 1 month after percutaneous coronary 
intervention).
Test* Group PUFA (n = 20) Group C (n = 20) P
Mean ± SD 25–75 percentile Mean ± SD 25–75 percentile
Delta ADP 3.8 ± 12.0 –3.5/11 5.0 ± 10.4 –6/12 0.73
Delta ASPI 8.5 ± 25.0 –1/13.5 –3.9 ± 24.1 –4/13 0.12
Delta COL 2.7 ± 15.3 –4/11.5 2.8 ± 11.2 –5/10 0.98
Delta TRAP 14.3 ± 19.7 3/25.5 18.2 ± 31.0 –6/31 0.63
*Platelets activity tests with different activators: arachidonic acid (ASPI), adenosine diphosphate (ADP), thrombin receptor activating  
  peptide-6 (TRAP), collagen (COL).
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were observed. In all patients examined, delta 
ADP and delta COL were correlated with the 
PTL count (r = –0.407, p = 0.008 and r = –0.534, 
p < 0.001); the PTL count correlated with delta 
COL (r = –0.624, p = 0.003) in the PUFA group 
and with delta ADP in the group C (r = –0.535, 
p = 0.02). 
In the PUFA group, delta ASPI correlated with 
the PTL-anisocytosis (r = 0.602, p = 0.005), PTL 
volume (r = 0.516, p = 0.019) and PTL distribution 
width (r = 0.547, p = 0.012). 
In all patients examined there were also 
significant correlations between the TRAP test 
results and the PTL count (r = 0.409, p = 0.006) 
and between the COL test values and both 
the mean PTL volumes (r = 0.342, p = 0.024) 
and the PLT distribution width (r = 0.363, 
p = 0.018).
Multivariate correlation analysis did not reveal 
any statistically significant associations.
Discussion
In the present study, we assessed the effect 
of the co-administration of the recommended dose 
of N-3 PUFA with dual antiplatelet therapy (ASA 
with CLO) on the values of the PLT function tests. 
The results showed that N-3 PUFA did not affect 
the efficacy of dual antiplatelet therapy.
The PTL reactivity assessed 18–24 h after 
the PCI and CLO loading dose were comparable to 
the results after a 1-month follow-up. The degree 
of PTL suppression was typical — low values of 
the ADP, ASPI and COL tests were observed 
with higher values of the TRAP test. The TRAP 
test mainly represents the platelet-activation of 
thrombin and thus constitutes a sensitive marker 
of IIb/IIIa antagonists; CLO only exerts a weak 
effect on the TRAP test [19]. The relatively high 
on-treatment PTL aggregation that was observed 
in both groups could be associated with the high 
prevalence of hypertension, hyperlipidemia and 
diabetes. 
In addition, we did not observe any differences 
in the clinical outcome of the study groups. The 
supplementation did not interfere with the clinical 
efficacy of antiplatelet therapy. It can be concluded 
that N-3 PUFA supplementation in the recom-
mended standard dose does not increase the risk 
for restenosis or the risk of bleeding. 
There are some data on N-3 PUFA induced 
PTL inhibition in the literature; however, the exact 
mechanism of the process is not well understood 
[20]. The study of Larson et al. [21] showed that 
omega-3 fatty acids in a daily dose of 3.4 g may 
modulate collagen signaling in human platelets. 
Our observations did not reveal any difference in 
COL test results after the administration of 1.0 g 
N-3 PUFA. The study of Cohen et al. [22] revealed 
that escalating doses of N-3 PUFA from 1 g to 8 g 
daily provided an increase in mean bleeding time 
in a dose-dependent manner. The study was per-
formed in subjects with no antiplatelet agent, in 
subjects with ASA and ASA plus CLO. Finally, the 
authors concluded that N-3 PUFA attenuates PTL 
activation even among patients taking ASA or ASA 
plus CLO. This was associated with an increase in 
the negative PTL surface charge as well as with 
the production of thromboxan A3 from N-3 PUFA. 
Thus, N-3 PUFA may exert a synergistic effect with 
established antiplatelet agents [22]. In the same 
study groups, light transmission aggregometry 
(LTA) did not detect any additional antiplatelet ef-
fects of N-3 PUFA, which was in agreement with 
our findings. We may suspect that both LTA and 
WBA may not be sensitive enough tools to detect 
subtle changes in PTL function. 
There is limited data on the relationship be-
tween blood coagulation and the administration 
of 1.0 g N-3 PUFA daily in the literature [4, 5, 
16–18]. Most of the research did not confirm 
any interactions [4, 5, 18]. According to the 
recently published data, 1.0 g N-3 PUFA daily 
added to the standard dual antiplatelet therapy 
after PCI influences PTL response to CLO [16, 
17]. The authors in the studies with a protocol 
similar to our study demonstrated both a lower 
P2Y12 reactivity index and adenosine induced 
PTL aggregation in the group treated with ASA, 
CLO and N-3 PUFA [16, 17]. The PTL light 
transmission aggregometry in PTL-poor plasma 
and the vasodilator-stimulated phosphoprotein 
test (VASP) were used, which did not allow for 
a reliable comparison to our findings.
High dose N-3 PUFA treatment may reduce 
PTL and erythrocyte cell count slightly [23]. We 
only assessed the baseline blood cell morphology, 
thus we were not able to verify any impact of 
1.0 g N-3 PUFA on these parameters.
The additional finding of the study was the 
relationship between the results of the PTL func-
tion tests and the clinical data. These findings are in 
accordance with previously published observations 
[23, 24] and suggest that the analysis of standard 
morphology, i.e. PTL count, may be helpful in the 
prediction of ASA and CLO responsiveness. More-
over, we  found age, serum lipids and creatinine to 
be modifying factors for PTL test results. 
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There are some limitations as well as ad-
vantages of the study. Our study had a relatively 
limited sample size; however, the well-matched 
study groups allowed for an objective analysis. 
The follow-up was only at the first month after 
PCI; however, 2 arguments were taken into ac-
count. Firstly, this is the most important period for 
the appearance of in-stent thrombosis. Secondly, 
standard dual antiplatelet therapy after elective 
PCI with BMS implantation was recommended for 
4–6 weeks [1]. We did not find any differences in 
the end-points between the study groups, which 
did not allow us to establish whether N-3 PUFA 
influences the clinical outcomes during follow-up. 
This issue requires a different study protocol and 
a larger study group. 
There are some disadvantages for all PTL 
function assays. Most tests are not standardized 
and there are no reference values available [25, 26]. 
Lordkipanidze et al. [27] did not observe a strong 
correlation between different PTL function tests. 
We were aware of these limitations and therefore 
we used one, novel test — WBA — and compared 
the results of the same patients at 2 points in time 
— before and after therapeutic intervention. WBA 
is a reliable method for PTL function evaluation 
that allows antiplatelet therapy to be monitored 
in clinical practice and for clinical investigations. 
However, we cannot exclude that certain assays 
may not be suitable to detect  all effects on PTL 
function. 
On the other hand, we should be aware that 
CLO co-prescription makes it very difficult to 
specifically evaluate the aspirin response, since 
P2Y12-inhibitors affect aspirin‘s inhibition of ara-
chidonic acid-induced PTL aggregation [28, 29].
According to the recently published data, we 
should also take into account the antithrombotic 
effects of N-3 PUFA supplementation in patients 
after PCI in stable CAD. It  was demonstrated that 
N-3 PUFA decreases thrombin formation and the 
activation of oxidative stress, favorably alters fibrin 
clot properties and may also exert some clinical 
effects  through these mechanisms [30]. The de-
creased thrombin generation induced by N-3 PUFA 
may contribute to lower PTL activation and finally 
to increased effects of antiplatelet drugs. In this 
setting, the TRAP test used in our study seemed 
to be important. The test used TRAP-6, a potent 
agonist which mimicks the PTL-activating action 
of thrombin. Our findings did not reveal any dif-
ferences in the TRAP test results after N-3 PUFA 
supplementation. 
Conclusions
Our results indicate that co-administration of 
the recommended N-3 PUFA dose does not impair 
the efficacy of dual antiplatelet therapy measured us-
ing WBA in patients with SAP after PCI. Since PTL 
activation and blood coagulation are interrelated, 
prospective clinical trials with complex laboratory 
analyses of the clotting system are necessary in 
order to evaluate the potential impact of N-3 PUFA 
on the efficacy of dual antiplatelet therapy as well 
as on thrombotic events following PCI.
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